<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00311155</url>
  </required_header>
  <id_info>
    <org_study_id>SP-OLM-03-05</org_study_id>
    <secondary_id>2005-004659-36</secondary_id>
    <nct_id>NCT00311155</nct_id>
  </id_info>
  <brief_title>Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension</brief_title>
  <acronym>OLMETREAT</acronym>
  <official_title>Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sankyo Pharma Gmbh</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety and efficacy of an add-on treatment algorithm with
      olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal Was Achieved.</measure>
    <time_frame>Baseline to ≤20 weeks</time_frame>
    <description>For non-diabetic participants the target seated blood pressure goals were: Systolic - ≤130 mm Hg; Diastolic - ≤85 mm Hg. For diabetic participants the target seated blood pressure goals were: Systolic - &lt;130 mm Hg; Diastolic - &lt;80 mm Hg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Normalized Blood Pressure Overall and for Each Treatment From Baseline to Completion of the Treatment During Which Blood Pressure Goals Were Achieved</measure>
    <time_frame>Baseline to ≤20 weeks</time_frame>
    <description>Normalized blood pressure is defined as a mean sitting systolic blood (sBP) pressure at trough of &lt;140 mmHg and mean sitting diastolic blood pressure (dBP)of &lt;90 mmHg for non-diabetic patients or a mean sitting sBP at trough of &lt;130 mmHg and mean sitting dBP &lt;80 mmHg for diabetic patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Diastolic Responders Overall and for Each Treatment From Baseline to the Completion of Treatment During Which Blood Pressure Goals Were Achieved.</measure>
    <time_frame>Baseline to ≤20 weeks</time_frame>
    <description>Diastolic responders were defined as a participant who is a normaliser or has a lowering of the mean sitting diastolic blood pressure of ≥10 mmHg at trough.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Systolic Responders Overall and for Each Treatment From Baseline to the Completion of the Treatment During Which Blood Pressure Goals Were Achieved</measure>
    <time_frame>Baseline to ≤20 weeks</time_frame>
    <description>Systolic responders defined as a participant who is a normaliser or has a lowering of the mean sitting systolic blood pressure of ≥20 mmHg at trough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Diastolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment</measure>
    <time_frame>Baseline to ≤20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Systolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment</measure>
    <time_frame>Baseline to ≤20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">694</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olmesartan medoxomil oral tablets for 4 weeks followed by, if necessary:
Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets for 8 weeks, followed by, if necessary:
Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets + amlodipine oral tablets for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary</intervention_name>
    <description>Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients age greater than or equal to 18 years with mild to moderate
             hypertension.

          -  Pre-treated patients with normal or elevated blood pressure (BP) are eligible to
             participate if their pre-treatment medication can be withdrawn. At the end of the
             placebo run-in period sitting systolic BP greater than or equal to 140 and less than
             180 mmHg and/or sitting diastolic BP greater than or equal to 90 and less than 110
             mmHg at trough.

        Exclusion Criteria:

          -  Female patients of childbearing potential must not be pregnant or lactating and must
             be using adequate contraception.

          -  Patients with serious disorders which may limit the ability to evaluate the efficacy
             or safety of the test drug(s), including cardiovascular, renal, pulmonary, hepatic,
             gastrointestinal, endocrine/metabolic, haematological/oncological, neurological and
             psychiatric diseases.

          -  Patients within the last 6 months having a history of myocardial infarction, unstable
             angina pectoris, percutaneous coronary intervention, heart failure, cerebrovascular
             accident, or transient ischemic attack.

          -  Patients with clinically significant elevations in laboratory values at Screening
             Visit.

          -  Patients with secondary hypertension of any etiology, such as renal disease,
             pheochromocytoma, or Cushing's syndrome.

          -  Patients with contraindications for olmesartan medoxomil, hydrochlorothiazide, and/or
             amlodipine besylate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Heagerty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester, Dept. of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fulpmes</city>
        <zip>6166</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Klinik, F. Innere Medizin</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kundl</city>
        <zip>6250</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonissen-Krankenhaus Hospital</name>
      <address>
        <city>Salzburg-Aigen</city>
        <zip>5026</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1080</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mechelen</city>
        <zip>2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Bois de l`Abbaye et de Hesba, Department of Intensive Care</name>
      <address>
        <city>Seraing</city>
        <zip>4100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeen Ziekenhuis Maria-Middelares, Cardiologie, Campus de Pelikaan</name>
      <address>
        <city>Temse</city>
        <zip>9140</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ancerville</city>
        <zip>55170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bourges</city>
        <zip>18000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Derval</city>
        <zip>44590</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble</city>
        <zip>38100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montrevel en Bresse</city>
        <zip>01340</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pouilly en Auxois</city>
        <zip>21320</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poussan</city>
        <zip>34560</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sorcy Saint Martin</city>
        <zip>55190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Aubin des Châteaux</city>
        <zip>44110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Etienne de Montluc</city>
        <zip>44360</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Priest</city>
        <zip>69800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yerres</city>
        <zip>91330</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annweiler</city>
        <zip>76855</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Balve</city>
        <zip>58802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bammental</city>
        <zip>69245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Krankenhaus Bielefeld, Medizinische Klinik in Bethel - Gilead I</name>
      <address>
        <city>Bielefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haag</city>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20148</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg (Neuenheim)</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mühldorf / Inn</city>
        <zip>84453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schwenningen</city>
        <zip>78054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>VS-Villingen</city>
        <zip>78050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weyhe</city>
        <zip>28844</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regina Apostolorum</name>
      <address>
        <city>Albano Laziale (RM)</city>
        <zip>00041</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale C.G. Mazzoni</name>
      <address>
        <city>Ascoli Piceno</city>
        <zip>63100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Nuovo Cutroni</name>
      <address>
        <city>Barcellona Pozzo di Gotto (ME)</city>
        <zip>98051</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura &quot;La Madonnina&quot;</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Sebastiano</name>
      <address>
        <city>Caserta</city>
        <zip>81100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi &quot;G. D'Annunzio&quot;</name>
      <address>
        <city>Chieti Scalo</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Madonna delle Grazie&quot;</name>
      <address>
        <city>Matera</city>
        <zip>75100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Paolo</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Carlo Borromeo</name>
      <address>
        <city>Milano</city>
        <zip>20153</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero San Lorenzo</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Portogruaro</name>
      <address>
        <city>Portogruaro (VE)</city>
        <zip>30026</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Universitario a Gestione Diret</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Elvas</name>
      <address>
        <city>Elvas</city>
        <zip>7350-954</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hertogenbosch</city>
        <zip>5216 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hilversum</city>
        <zip>1214 JR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lieshout</city>
        <zip>5737 CB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waalwijk</city>
        <zip>5144 CB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Almada</name>
      <address>
        <city>Almada Almada</city>
        <zip>2801-951</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fernando da Fonseca</name>
      <address>
        <city>Amadora Amadora</city>
        <zip>2720-276</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de. S. Marta</name>
      <address>
        <city>Lisboa Lisboa</city>
        <zip>1169-024</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum Oberdorf</name>
      <address>
        <city>Affoltern am Albis</city>
        <zip>8910</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gland</city>
        <zip>1196</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petit-Lancy</city>
        <zip>1213</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dreispitz</name>
      <address>
        <city>Zurich</city>
        <zip>8050</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Atherstone Surgery</name>
      <address>
        <city>Atherstone</city>
        <zip>CV9 1EU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Centre</name>
      <address>
        <city>Birmingham</city>
        <zip>B37 7TR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterloo Medical Centre</name>
      <address>
        <city>Blackpool</city>
        <zip>FY4 3AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rowden Surgery</name>
      <address>
        <city>Chippenham</city>
        <zip>SN15 2SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Gables Medical Centre</name>
      <address>
        <city>Coventry</city>
        <zip>CV6 4DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridge Medical Centre</name>
      <address>
        <city>Crawley</city>
        <zip>RH10 1LL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homefield Surgery</name>
      <address>
        <city>Exeter</city>
        <zip>EX1 2QS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodside Health Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 7LR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castle Milk Health Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G45 9 AW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Cardiovascular and Endocrine Sciences</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakside Surgery</name>
      <address>
        <city>Plymouth</city>
        <zip>PL5 3PY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwood Medical Centre</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovemead Group Practice</name>
      <address>
        <city>Trowbridge</city>
        <zip>BA14 7EG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2006</study_first_submitted>
  <study_first_submitted_qc>April 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2006</study_first_posted>
  <results_first_submitted>October 12, 2010</results_first_submitted>
  <results_first_submitted_qc>October 12, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 10, 2010</results_first_posted>
  <disposition_first_submitted>October 12, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>October 12, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 10, 2010</disposition_first_posted>
  <last_update_submitted>November 23, 2010</last_update_submitted>
  <last_update_submitted_qc>November 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Senior Manager - Study Coordination</name_title>
    <organization>Daiichi Sankyo Europe, GmbH</organization>
  </responsible_party>
  <keyword>Olmesartan medoxomil</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted between April 2006 and April 2008 in 9 European countries at 58 investigational sites. The countries participating were: Austria, Belgium, France, Germany, Italy, The Netherlands, Portugal, Switzerland, and United Kingdom.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed</title>
          <description>Olemesartan 20 mg to start. Hydrochlorothiazide 12.5 mg and then 25 mg was added, if necessary. If blood pressure goal was still not achieved, amlodipine 5 mg and then 10 mg were added, if needed. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="694"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="601">Some participants had multiple reasons for discontinuation</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet entry criteria</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed</title>
          <description>Olemesartan 20 mg to start. Hydrochlorothiazide 12.5 mg and then 25 mg was added, if necessary. If blood pressure goal was still not achieved, amlodipine 5 mg and then 10 mg were added, if needed. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="694"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.16" spread="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.16" spread="16.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.86" spread="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal Was Achieved.</title>
        <description>For non-diabetic participants the target seated blood pressure goals were: Systolic - ≤130 mm Hg; Diastolic - ≤85 mm Hg. For diabetic participants the target seated blood pressure goals were: Systolic - &lt;130 mm Hg; Diastolic - &lt;80 mm Hg.</description>
        <time_frame>Baseline to ≤20 weeks</time_frame>
        <population>691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed</title>
            <description>Olmesartan (OLM) 20 mg to start for 4 weeks. Hydrochlorothiazide (HCTZ) 12.5 mg is added, if necessary, for 4 additional weeks. Hydrochlorothiazide is doubled (25 mg), if necessary, for 4 additional weeks. If blood pressure goals were still not achieved, amlodipine (AML) 5 mg was added to the olmesartan and hydroclorothiazide for an additional 4 weeks. Finally, the amplodine was doubled (10 mg), if needed, for the final 4 weeks of treatment. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg. The subject's participation in the study was concluded as soon as blood pressure goals were met.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal Was Achieved.</title>
          <description>For non-diabetic participants the target seated blood pressure goals were: Systolic - ≤130 mm Hg; Diastolic - ≤85 mm Hg. For diabetic participants the target seated blood pressure goals were: Systolic - &lt;130 mm Hg; Diastolic - &lt;80 mm Hg.</description>
          <population>691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="691"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall N=691</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg N=688</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg+HCTZ 12.5 mg N=580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg+HCTZ 25 mg N=446</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg+HCTZ 25 mg+AML 5 mg N=296</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg+HCTZ 25 mg+AML 10 mg N=176</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Normalized Blood Pressure Overall and for Each Treatment From Baseline to Completion of the Treatment During Which Blood Pressure Goals Were Achieved</title>
        <description>Normalized blood pressure is defined as a mean sitting systolic blood (sBP) pressure at trough of &lt;140 mmHg and mean sitting diastolic blood pressure (dBP)of &lt;90 mmHg for non-diabetic patients or a mean sitting sBP at trough of &lt;130 mmHg and mean sitting dBP &lt;80 mmHg for diabetic patients.</description>
        <time_frame>Baseline to ≤20 weeks</time_frame>
        <population>691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed</title>
            <description>Olmesartan (OLM) 20 mg to start for 4 weeks. Hydrochlorothiazide (HCTZ) 12.5 mg is added, if necessary, for 4 additional weeks. Hydrochlorothiazide is doubled (25 mg), if necessary, for 4 additional weeks. If blood pressure goals were still not achieved, amlodipine (AML) 5 mg was added to the olmesartan and hydroclorothiazide for an additional 4 weeks. Finally, the amplodine was doubled (10 mg), if needed, for the final 4 weeks of treatment. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg. The subject's participation in the study was concluded as soon as blood pressure goals were met.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Normalized Blood Pressure Overall and for Each Treatment From Baseline to Completion of the Treatment During Which Blood Pressure Goals Were Achieved</title>
          <description>Normalized blood pressure is defined as a mean sitting systolic blood (sBP) pressure at trough of &lt;140 mmHg and mean sitting diastolic blood pressure (dBP)of &lt;90 mmHg for non-diabetic patients or a mean sitting sBP at trough of &lt;130 mmHg and mean sitting dBP &lt;80 mmHg for diabetic patients.</description>
          <population>691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="691"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall N=691</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg N=688</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 12.5 mg N=580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg N=446</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Diastolic Responders Overall and for Each Treatment From Baseline to the Completion of Treatment During Which Blood Pressure Goals Were Achieved.</title>
        <description>Diastolic responders were defined as a participant who is a normaliser or has a lowering of the mean sitting diastolic blood pressure of ≥10 mmHg at trough.</description>
        <time_frame>Baseline to ≤20 weeks</time_frame>
        <population>691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed</title>
            <description>Olmesartan (OLM) 20 mg to start for 4 weeks. Hydrochlorothiazide (HCTZ) 12.5 mg is added, if necessary, for 4 additional weeks. Hydrochlorothiazide is doubled (25 mg), if necessary, for 4 additional weeks. If blood pressure goals were still not achieved, amlodipine (AML) 5 mg was added to the olmesartan and hydroclorothiazide for an additional 4 weeks. Finally, the amplodine was doubled (10 mg), if needed, for the final 4 weeks of treatment. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg. The subject's participation in the study was concluded as soon as blood pressure goals were met.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Diastolic Responders Overall and for Each Treatment From Baseline to the Completion of Treatment During Which Blood Pressure Goals Were Achieved.</title>
          <description>Diastolic responders were defined as a participant who is a normaliser or has a lowering of the mean sitting diastolic blood pressure of ≥10 mmHg at trough.</description>
          <population>691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="691"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall N=691</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg N=688</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 12.5 mg N=580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg N=446</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Systolic Responders Overall and for Each Treatment From Baseline to the Completion of the Treatment During Which Blood Pressure Goals Were Achieved</title>
        <description>Systolic responders defined as a participant who is a normaliser or has a lowering of the mean sitting systolic blood pressure of ≥20 mmHg at trough</description>
        <time_frame>Baseline to ≤20 weeks</time_frame>
        <population>691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed</title>
            <description>Olmesartan (OLM) 20 mg to start for 4 weeks. Hydrochlorothiazide (HCTZ) 12.5 mg is added, if necessary, for 4 additional weeks. Hydrochlorothiazide is doubled (25 mg), if necessary, for 4 additional weeks. If blood pressure goals were still not achieved, amlodipine (AML) 5 mg was added to the olmesartan and hydroclorothiazide for an additional 4 weeks. Finally, the amplodine was doubled (10 mg), if needed, for the final 4 weeks of treatment. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg. The subject's participation in the study was concluded as soon as blood pressure goals were met.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Systolic Responders Overall and for Each Treatment From Baseline to the Completion of the Treatment During Which Blood Pressure Goals Were Achieved</title>
          <description>Systolic responders defined as a participant who is a normaliser or has a lowering of the mean sitting systolic blood pressure of ≥20 mmHg at trough</description>
          <population>691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="691"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall N=691</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg N=688</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 12.5 mg N=580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg N=446</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Diastolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment</title>
        <time_frame>Baseline to ≤20 weeks</time_frame>
        <population>691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed</title>
            <description>Olmesartan (OLM) 20 mg to start for 4 weeks. Hydrochlorothiazide (HCTZ) 12.5 mg is added, if necessary, for 4 additional weeks. Hydrochlorothiazide is doubled (25 mg), if necessary, for 4 additional weeks. If blood pressure goals were still not achieved, amlodipine (AML) 5 mg was added to the olmesartan and hydroclorothiazide for an additional 4 weeks. Finally, the amplodine was doubled (10 mg), if needed, for the final 4 weeks of treatment. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg. The subject's participation in the study was concluded as soon as blood pressure goals were met.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Diastolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment</title>
          <population>691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="691"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall N=691</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.73" spread="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg N=688</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.44" spread="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 12.5 mg N=580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.15" spread="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg N=446</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.04" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.03" spread="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.47" spread="8.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Systolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment</title>
        <time_frame>Baseline to ≤20 weeks</time_frame>
        <population>691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed</title>
            <description>Olmesartan (OLM) 20 mg to start for 4 weeks. Hydrochlorothiazide (HCTZ) 12.5 mg is added, if necessary, for 4 additional weeks. Hydrochlorothiazide is doubled (25 mg), if necessary, for 4 additional weeks. If blood pressure goals were still not achieved, amlodipine (AML) 5 mg was added to the olmesartan and hydroclorothiazide for an additional 4 weeks. Finally, the amplodine was doubled (10 mg), if needed, for the final 4 weeks of treatment. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg. The subject's participation in the study was concluded as soon as blood pressure goals were met.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Systolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment</title>
          <population>691 = the full analysis set (FAS). FAS consists of all participants who received trial medication and who had data from at least one post-baseline visit with regard to the primary efficacy parameter, i.e., both the systolic and the diastolic blood pressure (BP) had to be measured. N is reduced for each treatment as subjects attain BP goals.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="691"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall N=691</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.58" spread="13.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg N=688</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.97" spread="11.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 12.5 mg N=580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.55" spread="12.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg N=446</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.51" spread="13.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.06" spread="13.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.02" spread="13.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The time frame was from baseline to up to 20 weeks of treatment</time_frame>
      <desc>Safety was addressed in terms of occurrences of adverse envents (AEs), of treatment-emergent AEs, changes in vital signs, ECGs, physical examination findings and laboratory parameters. AEs were documented during the whole study period by spontaneous reports to the investigator or upon questioning by or observations by the investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed</title>
          <description>Olemesartan 20 mg to start. Hydrochlorothiazide 12.5 mg and then 25 mg was added, if necessary. If blood pressure goal was still not achieved, amlodipine 5 mg and then 10 mg were added, if needed. Thus, the maximum combination was olmesartan 20mg + hydrochlorothiazide 25mg + amlodipine 10mg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Myocardial infacrtion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="293" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="694"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="694"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. Director, Regulatory Operations</name_or_title>
      <organization>Daiichi Sankyo Pharma Development</organization>
      <phone>732-590-5032</phone>
      <email>hmkessler@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

